VGX has developed proprietary technology for delivery of plasmids into skeletal muscle cells and skin. This unique technology optimizes plasmid uptake and subsequent expression by adapting an applied electric field strength real-time to sense the tissue micro-environment. This results in uniform expression of the target protein across the injected muscle fiber(s) with minimal or no tissue damage. Clinically effective results have been achieved when plasmids with historically low expression levels are delivered with the VGX™ electroporation device (CELLECTRA^® electroporation).

GFP is expressed in Flexor Digitorum Brevis (FDB) muscle in mice following electroporation using CELLECTRA® EP. (Courtesy of S. Puttini and N. Mermod, Univ. of Lausanne, Switzerland)	VGX has also developed muscle specific promoters ensuring that the target protein of interest is expressed only in the muscle fibers. This is an important consideration for the development of DNA therapeutics and vaccines in that it introduces an additional margin of safety in assessing unintended biodistribution and integration of the injected plasmid at sites/organs distal from the injection site.